Ultragenyx Pharmaceutical Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
60 LEVERONI COURT, NOVATO, CA, 94949
Mailing Address
60 LEVERONI COURT, NOVATO, CA, 94949
Phone
415-483-8800
Fiscal Year End
1231
EIN
272546083
Financial Overview
FY2025
-$569.00M
Net Income
$1.60B
Total Liabilities
$352.00M
Stockholders' Equity
$-5.83
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | March 27, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
Annual Reports
10-K
February 18, 2026
- Total revenue surged by 28% year-over-year to $485 million in fiscal year 2023, driven by strong product demand.
- Net loss narrowed by 15% to $280 million, reflecting improved operational efficiency and rising product sales.
Material Events
8-K
Strategy Change
December 29, 2025
High Impact
- Ultragenyx's experimental drug setrusumab (UX143) failed to meet its primary goal in two late-stage (Phase 3) clinical trials (Orbit and Cosmic) for Osteogenesis Imperfecta (OI).
- The drug did not significantly reduce bone fractures, which was its main objective for regulatory approval.
Insider Trading
STRONG SELL
7 insiders
15 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.